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Objective: Cerebral sinus venous thrombosis (CSVT) is a disease that can be seen 
in all age groups with various clinical findings and usually a good prognosis. In 
this study, evaluation of the complaints on admission, the possible risk factors, 
localization, findings and treatment approaches, and discussion of these findings 
with comparison to the literature were aimed.
Materials and Methods: The demographic, clinical, laboratory and the radiological 
characteristics of 19 patients with diagnosed with CSVT and followed at the 
Sakarya University Training and Research Hospital Clinic of Neurology.
Results: Nineteen patients (15 female, 4 male) with the diagnosis of CSVT were 
included. The mean age of the patients was determined as 31.3±11.2. Headache 
was determined to be the first symptom on admission in 17 patients. Nausea-
vomiting (n=10), blurred vision (n=4) and epileptic seizures (n=3) had accompanied 
headache. Altered state of consciousness (n=2), papilledema (n=4), dysarthria 
(n=1), and cerebellar disorder (n=1) were determined. Two of the patients were 
pregnant and 6 patients were in the postpartum period. CSVT due to infection was 
determined in 2 patients. No reason for etiological investigation was found in 4 of 
the cases. In 11 patients, more than one etiology were detected. Two patients had 
been diagnosed with Behçet’s disease. MTHFR A1298C gene heterozygous mutation 
was most detected. Fourteen patients were determined to have a single sinus 
venous thrombosis and 5 patients had more than one sinus venous thrombosis on 
magnetic resonance venography. Six patients had venous infarction.
Conclusion: Pregnancy and postpartum period are significant risk factors for 
CSVT. The association of more than one reason in the etiological investigations of 
patients despite the presence of one significant risk factor has been emphasized.
Öz
Amaç: Serebral sinüs venöz trombozu (SSVT) her yaş grubunda rastlanılabilen, çok 
çeşitli klinik bulgulara ve genellikle iyi prognoza sahip bir hastalıktır. Bu çalışmada 
hastaların başvuru şikayetleri, olası risk faktörleri, lokalizasyonu, bulguları ve 
tedavi yaklaşımlarımızın ortaya konulması ve bulgularımızın literatürle tartışılması 
amaçlanmıştır.
Gereç ve Yöntemler: Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi Nöroloji 
Kliniği’nde SSVT tanısı alarak izlenmiş olan 19 hastanın demografik, klinik, 
laboratuvar ve radyolojik özellikleri değerlendirilmiştir.
Bulgular: SSVT tanısı alan 19 hasta (15 kadın, 4 erkek) alındı. Hastaların yaş 
ortalamaları 31,3±11,2 idi. Baş ağrısı 17 hastada ilk başvuru şikayeti olarak saptandı. 
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Introduction
Cerebral sinus venous thrombosis (CSVT) is a disease 
that can be seen in all age groups with various clinical 
findings and usually a good prognosis. It comprises 
around 0.5% of all causes of cerebrovascular stroke 
(1). Despite the disease being observed at all age 
groups, it is more commonly seen in adult females. 
The most important known etiologies are pregnancy 
and the postpartum period, oral contraceptives 
(OCPs), systemic inflammatory diseases, malignancy, 
infections, coagulation disorders and hematological 
diseases. The diagnosis and the awareness about the 
disease, which usually has a good prognosis, have 
increased because of advanced imaging techniques.
Materials and Methods
The clinical and the radiological characteristics of 
19 patients admitted to the Sakarya University Training 
and Research Hospital Clinic of Neurology and the 
Adult Emergency Service and treated in the neurology 
ward with the diagnosis of cerebral venous thrombosis 
(CVT) between 2011 and 2014 were evaluated in this 
study. The demographic, clinical, laboratory and the 
radiological findings of the patients were investigated. 
In this study, evaluation of the complaints on 
admission, the risk factors, localization of CSVT, 
findings and treatment approaches, and discussion of 
these findings with comparison to the literature were 
aimed. Vitamin B12, folic acid, thyroid stimulating 
hormone and the C-reactive protein levels of the 
patients, in addition to routine laboratory tests, were 
recorded. Homocysteine (HS), anti-nuclear antibody 
(ANA), anti-cardiolipin antibody (ACA), fibrinogen, 
active protein C resistance (APCR), anti-thrombin III 
(AT III), protein C (PC), protein S (PS), factor V Leiden 
(FVL) mutation, prothrombin gene G20210A mutation 
(Prt G2021A), methylene tetrahydrofolate reductase 
(MTHFR) C677T and A1298C gene mutations were 
analyzed in most of the cases where possible. The 
diagnosis of the disease was established according 
to the cranial magnetic resonance imaging (MRI) and 
cranial MRI venography, and the patients who were 
investigated with these imaging techniques were 
included for the evaluation. All procedures performed 
in studies involving human were in accordance with 
the ethical standards of Sakarya University Training 
and Research Hospital at which the studies were 
conducted (approval no: 71522473/050.01.04/66). 
Informed consent was obtained from the patients.
Results
A total number of 19 patients with the diagnosis 
of CSVT were included in the study. Table 1 presents 
the main characteristics of the patients. Fifteen of the 
patients were female and 4 were male. The mean age 
of the patients was determined as 31.3±11.2, while 
the mean age of the female patients was determined 
as 30.7±11.1.
Headache was determined to be the complaint 
on admission in 17 (89.4%) patients. Ten of the 
cases that had presented with headache also had a 
history of nausea-vomiting, 4 had blurred vision and 
3 had epileptic seizures. In addition, 1 patient had 
speech difficulty and 1 patient was admitted with 
the complaints of right-sided weakness, numbness 
and epileptic seizures. Altered state of consciousness 
was determined in 2 (10.5%) of the patients during 
the first examination. Furthermore, 4 (21.1%) patients 
had papilledema, 1 (5.3%) patient had dysarthria, 
and 1 (5.3%) patient had cerebellar disorder. Two 
(10.5%) of the patients were pregnant and 6 (31.6%) 
patients were in the postpartum period. None of the 
patients reported OCPs intake. Malignancy, immune 
suppression and thrombotic disease were not seen 
in the history of the patients. Infectious CVT was 
determined in 2 (10.5%) patients, one of which had 
mastoiditis and the other had dental abscess. Iron 
deficiency anemia was observed in 4 (21.1%) patients. 
No etiological reason underlying the condition was 
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Baş ağrısına bulantı-kusma (n=10), bulanık görme (n=4), epileptik nöbet geçirme (n=3) eşlik ediyordu. Bilinç bulanıklığı (n=2), papil 
ödem (n=4), dizartri (n=1), serebellar bozukluk (n=1) tespit edildi. Hastalardan 2’si gebe, 6’sı postpartum dönemde idi. İki hastada 
enfeksiyona bağlı SSVT saptandı. Dört hastada etiyolojik araştırmada bir neden bulunamadı. On bir hastada birden fazla etiyoloji 
saptandı. İki hastaya Behçet hastalığı tanısı kondu. En fazla MTHFR A1298C heterozigot gen mutasyonu saptandı. Manyetik rezonans 
venografide 14 hastada tek, 5 hastada birden fazla sinüste venöz tromboz saptandı. Altı hastada venöz enfarkt saptandı.
Sonuç: Gebelik ve postpartum dönem SSVT için önemli risk faktörleridir. Hastaların etiyolojik araştırmasında belirgin risk faktörü 
varlığında bile birden çok nedenin birlikteliği vurgulanmıştır.
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found in 4 (21.1%) of the cases. In 11 (57.9%) patients, 
more than one etiology were detected. Two (10.5%) 
patients had been diagnosed with Behçet’s disease 
as a result of the etiological investigation. Also 6 
(31.6%) patients had a history of smoking. Three 
(25%) of 12 patients undergoing investigation for 
ANA tested positive, while all 12 patients undergoing 
investigations for ACA tested negative. In the genetic 
analysis, 1 (6.7%) of 15 patients evaluated for FVL 
gene mutation were heterozygous, 2 (13.3%) of 15 
patients evaluated for Prt G20210A gene mutation 
were heterozygous, 2 (13.3%) of 15 patients evaluated 
for MTHFR C677T gene mutation were heterozygous 
and 2 (13.3%) of them were homozygous; 7 (46.7%) 
of 15 cases evaluated for MTHFR A1298C gene 
mutation were heterozygous and 1 (6.7%) of them 
was homozygous. Three (21.4%) of 14 patients 
undergoing HS level testing were determined to have 
high levels of HS. Two of the patients determined to 
have hyperhomocysteinemia, also had accompanying 
MTHFR A1298C gene mutation. Two (15.4%) of 
13 patients checked for PC and PS levels had PC 
deficiency and 3 (23.1%) of them were determined 
to have PS deficiency. AT III levels were found to be 
within the normal range in all 13 patients undergoing 
evaluation. Hyperfibrinogenemia was determined in 
1 (11.1%) out of 9 patients evaluated for fibrinogen 
levels. The heterozygous form was determined in 2 
(20%) out of 10 patients evaluated for APCR levels. 
The diagnosis of the disease was established by 
cranial MRI and MRI venography. Fourteen (73.7%) 
patients were determined to have a single sinus 
venous thrombosis and 5 (26.3%) patients had more 
than one sinus venous thromboses. Venous infarction 
was determined in 6 (31.6%) of the patients (Figure 
1a-d).
Discussion
CSVT has been reported to be more common 
among females. Similarly, it was determined to be 
more common among female patients at a rate of 
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Table 1. Demographic and clinical features of patients
Age Sex 
Symptom Sinus 
involvement Etiology 
1 26 F H Single Pregnant, PS def, MTFHRA homo
2 19 F H Single Postpartum, MTHFRA hetero
3 18 F H Single Postpartum
4 38 M H-NV-BV Single MTHFRC homo, HS, ANA
5 24 F H-NV-BV Single PC def, ANA, MTHFRA hetero, HS, hypofibrinogenemia
6 32 M H Single MTHFRA+MTHFRC hetero
7 31 F H Single Postpartum, PS def, ANA, MTHFRA hetero
8 57 F H-NV-S Single -
9 19 F H-NV-BV-AS Multiple Pregnant, IDA, PS def, Prt+MTFHRA hetero
10 32 F H-BK-BV Single Infection, MTHFRC homo, IDA, HS
11 18 F H-NV-S Multiple Postpartum, PC def, FVL+Prt+MTHFRC hetero
12 43 F SD Multiple Infection, IDA, MTHFRA hetero
13 44 F H Single MTHFR hetero
14 37 F H-NV-AS Single -
15 46 M H Single -
16 29 F H-NV-N Single Postpartum, IDA
17 23 F WN-S Multiple Postpartum
18 40 F H-NV Multiple -
19 19 M H-NV Single HS
H: Headache, NV: Nause-vomiting, BV: Blurred vision, S: Seizure, AS:Altered state of consciousness, WN: Weakness numbness, SD: Speech difficulty, 
IDA: Iron deficiency anemia, HS: Hyperhomocysteinemia, F: Female, M: Male
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78.9% in our study. The study reported that the male/
female ratio was reported as 1:1.29 (2). The age 
distribution among males has a homogenous 
distribution. However, the 20-35 years age range is 
more common at a rate of 61% in female patients. 
This type of age distribution is thought to be caused 
by pregnancy and OCP intake (3). The mean age was 
determined as 32±11.13 in a study evaluating 51 
patients (4). Similarly, the mean age was calculated as 
31.3±11.2 years in our study, and the mean age of the 
female patients was determined as 30.7±11.1 years. 
Headache is the most common presenting symptom 
of CSVT. In one study, headache was observed at a 
rate of 65.5% and it was seen at a rate of 80% in 
another study (5,6). Similarly, the complaint on 
admission was headache in 89.4% of the cases in our 
study. Headache is usually accompanied by another 
symptom. In our study, headache was also 
accompanied by other neurological findings in 64.7% 
of the cases. Chronic daily headache without any 
other neurological deficit was determined in 10.6% of 
the cases in a study evaluating 47 patients (6). Nausea 
and vomiting due to increased intracranial pressure 
can be accompanying symptoms. Nausea and vomiting 
were present in 58.9% of the cases complaining of 
headache. Seizures, hemiparesis and altered state of 
consciousness can be observed in the symptomatology. 
Four of our patients had seizures and altered state of 
consciousness was present in 2 patients. Wide 
different causes are among the etiologies of CSVT. In 
our study 10.5% (n=2) of cases were pregnant and 
31.6% (n=6) were in the postpartum period. Pregnancy 
is an important prothrombotic state. Coagulation 
proteins such as von Willebrand factor, factor VIII, 
factor V and fibrinogen are increased, PS is decreased 
and APCR develops during pregnancy (7,8). In a study, 
it was shown that venous thromboembolism (VTE) 
increased by 10-fold during pregnancy (9). In our 
study, one case was in the first trimester and the other 
case was diagnosed with CSVT in the last trimester. 
The risk of CSVT is the same for all trimesters during 
pregnancy; however, the frequency is increased 
during the postpartum period (10,11). The postpartum 
period was determined to be the most common cause 
with 33.3% of the patients in one study (4). 
Furthermore, a 3 to 8-fold increased risk in the 
postpartum period compared to the period before 
delivery has been determined in the literature (12). 
More than almost half of the CSVT cases developing in 
the postpartum period occur without any other 
triggering causes in the 3rd-4th days after delivery. Six 
patients in our study were in the postpartum period 
and it was observed that the cases were diagnosed on 
the 5th, 7th, 20th, 40th, 60th and the 180th days 
postpartum. CSVT can develop during the course of 
systemic infections. In a case series including 14 cases 
of CSVT, 4 patients were determined to have infection 
(13). CSVT occurs frequently during bacterial and 
fungal diseases; however, it can be observed during 
parasitic and viral diseases as well. The frequency of 
thrombosis due to infectious causes such as sinusitis, 
otitis media and mastoiditis is decreased as a result of 
common antibiotic administration. Untreated dental 
abscess and mastoiditis were determined in 2 of our 
cases (10.5%). These cases were evaluated as 
infection-caused CSVT. Iron deficiency anemia is a rare 
cause of CSVT in adults. Secondary thrombocytosis, 
hypercoagulability due to increased viscosity and 
increased metabolic stress caused by iron deficiency 
anemia are suggested hypotheses. In one study, the 
Figure 1. a, b) Diffusion, ADC magnetic resonance imaging showed that venous enfarkt on right occipital area, c) hyperintensity 
consistent with venous enfarkt on fluid-attenuated inversion recovery imaging, d) magnetic resonance venography showed 
occlusion of right transvers and sigmoid sinus
a b c d
189
Meandros Med Dent J 2018;19:185-91
Özözen Ayas et al. Cerebral Sinus Thrombosis: Nineteen Patients
risk of developing CSVT was reported to be significantly 
higher in severe iron deficiency anemia patients 
compared to the control group (10). In our study, iron 
deficiency anemia was determined in 21.1% (n=4) of 
the cases. However, all these patients also either had 
pregnancy, were in the postpartum period, had 
infection or genetic mutations, and therefore, iron 
deficiency anemia-caused CSVT was not considered in 
any of these patients. FVL mutation is the most 
commonly seen genetic risk factor in VTE (3). The 
anticoagulation characteristic of APC is deteriorated 
by FVL, which is also called mutant factor, and the 
tendency towards thrombosis is increased (14). The 
FVL allele frequency in the general population is 
reported as 1-8%. The FVL gene mutation incidence 
was reported as 10% in a study including the Turkish 
population (15). Dentali et al. (16) reported FVL gene 
mutation as a risk factor contributing to the 
development of CSVT. Heterozygous FVL gene 
mutation increases the risk of thrombosis by 5-10 
fold, while homozygous mutations increase this risk 
by 50-100 fold (14). In other studies, a significant 
relationship between FVL gene mutation and CVT was 
determined (17,18). In our study, FVL gene mutation 
was investigated in 15 patients and heterozygous 
mutation was determined in 1 case (6.7%). Prt 
G20210A mutation was shown to increase 
prothrombin levels in some studies, and to cause an 
increased risk of thrombosis by 2.7-3.8-fold and was 
reported as the second most common hereditary risk 
factor (14). The incidence of this mutation in patients 
diagnosed with CSVT has been reported as 11% and it 
is thought to cause a tendency towards thrombosis at 
higher rates than the FVL gene mutation alone (19). 
However, the estimated rate of this mutation for 
myocardial infarction, stroke or venous thrombosis 
was found as 1.05 in “The Physicians Health Study” 
evaluating 14916 cases prospectively (20). 
Heterozygous mutation was detected in 2 out of 15 
patients (13.3%) investigated for Prt G20210A gene 
mutation. MTHFR gene polymorphisms (C677T, 
A1298C) presenting a risk factor alone or through HS 
levels is controversial. The incidence of these 
polymorphisms in healthy individuals has also been 
reported (21). In one study analyzing 376 cases, the 
prevalence of MTHFR A1298C mutation was reported 
to be higher than the prevalence of MTHFR C677T. 
They reported that 44.8% of the patients were normal, 
42.3% were heterozygous mutant and 12.8% were 
homozygous mutant (21). According to the study 
conducted by Kluijtmans et al., (22) the MTHFR gene 
C677T variant shows a strong association with 
coronary artery diseases, peripheral artery diseases 
and venous thrombosis. The prevalence of 
homozygous mutant phenotype of MTHFR gene 
C677T variant has been reported as 5-9% in the 
Turkish population (23). In our study, 2 of 15 patients 
(13.3%) were determined to carry heterozygous and 2 
were determined to carry (13.3%) homozygous 
MTHFR C677T mutation. 7 out of 15 (46.7%) patients 
investigated for MTHFR A1298C mutation were 
determined to have heterozygous and 1 of them to 
have a homozygous mutation. These mutations are 
clinically relevant if they cause hyperhomocysteinemia 
(24). In our study, associated homozygous MTHFR 
A1298C gene mutation was determined in 2 patients. 
PC, PS and AT III deficiency are known causes of VTE; 
however, its importance in CSVT is not certain (19). In 
our study, 2 (15.5%) patients were determined to 
have PC deficiency, and 3 (23.1%) patients to have PS 
deficiency, while all patients were found to have 
normal AT III levels among the 15 patients who were 
investigated for PC, PS, AT III levels. Reasons such as 
pregnancy, postpartum period and genetic mutations 
were present in PC- and PS-deficient patients. 
Association of more than one risk factor is important 
in the etiological investigations for CVT patients. 
Systemic investigation of each risk factor is important 
even in patients with one significant risk factor. 
Presence of more than one risk factor has been 
emphasized to increase the thrombosis risk 
significantly (25). In our study, the rate of patients 
with more than one etiology was determined as 57.9% 
(n=11). In International Study CVT (Study on Cerebral 
Vein and Dural Sinus Thrombosis), 44% of the cases 
were reported to have more than one reason, and 
22% had hereditary thrombotic factors (26). Besides 
the variety in the etiology, no reason could be 
determined in 15% of the patients. No reason that 
could lead to CSVT was determined in 4 of our cases. 
ANA-positivity was determined in 3 patients as a 
result of vasculitis investigation and 1 of them was 
diagnosed with Behçet’s disease at the end of 2-year 
follow-up. Another patient was diagnosed with 
Behçet’s disease after the diagnosis of CSVT. CSVT is 
one of common neurological complications of 
Behçet’s disease (25). 
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MRI and MRI venography are the first choice 
of investigation for the diagnosis of CSVT. All 
patients in our study were diagnosed with MRI and 
MRI venography. Six (31.6%) of our patients were 
determined to have venous infarction. The most 
frequently affected sinuses are the superior sagittal, 
transverse, sigmoid, cavernous and the sinus rectus, 
respectively. In a case series reported by Azin and 
Ashjazadeh (27) including 61 cases of CSVT, in 80.3% 
of the cases, the thrombosis was detected in the 
superior sagittal sinus; the sigmoid sinus was affected 
in 6.5% and cavernous sinus thrombosis was detected 
in 4.9%. However, transverse sinus involvement was 
the most common in our study with 15 patients. 
Other more common localizations are found in the 
literature. In another study, sigmoid sinus involvement 
was observed in 74.5% of 47 patients (6). Transverse 
sinus involvement was determined in another study 
including 13 CSVT cases (28). Involvement of more 
than one sinus was observed in 65.5% of the cases in 
one study and 31.1% was observed in another study 
(5,13). A rate of around 30% is observed for more 
than one sinus involvement. Anticoagulant therapy is 
the first choice (29,30). Recently developed new oral 
anticoagulant medications are being investigated for 
new options for treatment of CSVT (31). Very good 
improvement was observed in 87% of 15 patients 
receiving dabigatran and followed with detection of 
80% recanalization (32). However, studies have been 
conducted with small numbers of patients and wider 
studies are required for higher efficiency (32,33). 
Anticoagulant treatment is our first choice despite 
the risk of increased hemorrhage, and 2 pregnant 
and 4 postpartum patients were treated with low 
molecular weight heparin and followed-up. CSVT has 
high morbidity and mortality if not diagnosed and 
treated early. 6-10% of the cases develop mortality 
despite adequate treatment (34). It was found that 
altered state of consciousness, hemorrhagic infarct, 
acute onset and hemiparesis were associated with 
an increased rate of mortality in a study including 47 
CSVT patients (6). We did not have any cases resulting 
with mortality in our study. In present study.
Study Limitations
Our study also had a limitation about number of 
patients. Future prospective studies in large numbers 
of patients are needed to better describe features of 
CSVT patients.
Conclusion
Pregnancy and postpartum period are significant 
risk factors for CSVT. The association of more than 
one reason in the etiological investigations of patients 
despite the presence of one significant risk factor has 
been emphasized.
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